Salute e Benessere

Lab Automation Market to be Worth $11.60 Billion by 2030: Grand View Research…

Read 200-page market research report, "Lab Automation Market Size, Share & Trends Analysis Report By Process (Continuous Flow, Discrete Processing), By Automation Type (Total Automation Systems, Modular Automation Systems), By End-use, By Region, And Segment Forecasts, 2023 - 2030", published by Grand View Research. Read 200-page market research report, " Lab Automation Market Size, Share & Trends Analysis Report By Process (Continuous Flow, Discrete Processing), By…

Glycated Albumin Assay Market worth $0.3 billion | MarketsandMarkets

Additionally, the aging population in developed and developing nations would favorably impact the market for glycated albumin assay. The prevalence of age-related illnesses like diabetes and pancreatic disorders is anticipated to rise dramatically as the senior population is forecast to grow quickly. Numerous test prescriptions to assess the levels of creatinine, albumin, glucose, ketones, and bilirubin are caused by diagnosing and treating such disorders, which is driving the market's…

Mendus AB: Report from the extraordinary general meeting of Mendus AB (publ) on…

At the extraordinary general meeting (the “ EGM ”) of Mendus AB (publ), reg. no. 556629-1786, (the “ Company ”), on 10 July 2023 the EGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the meeting and the complete proposals for resolutions, which have previously been published and are available on the Company's website,www.mendus.com. Amendment of the articles of association The EGM...

Race executes global license agreement with City of Hope to access FTO IP

A summary of the material terms of the Agreement can be found on page 3 of the ASX Announcement here. A summary of the material terms of the Agreement can be found on page 3 of the ASX Announcementhere. CEO and Managing Director,Damian Clarke-Brucecommented: "In 2020, City of Hope published research highlighting bisantrene as a potent inhibitor of FTO. This exclusive worldwide agreement secures access for Race to important IP associated with that work and opens exciting...

Safe group group reports half-year revenues of €2.9m

Safe group group reports half-year revenues of €2.9m Second-quarter revenue of €1.4M in Q2 2022, stable compared with Q1 2022 Safe Orthopaedics French half-year growth of 32%. Safe Medical half-year growth of 7% compared with 2022 Ongoing reorganization of less dynamic regions ...

NANOBIOTIX Announces License Agreement for Worldwide Co-development and…

PARIS and CAMBRIDGE, Mass., July10, 2023(GLOBE NEWSWIRE) -- NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the ''Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational,...

Plants to the Rescue

Of course onlookers were keen to know who was in need of medical help. Watching from afar one person noted something wasn't quite right – plants kept appearing/peeping out of the back of the ambulance and by the doors. Of course onlookers were keen to know who was in need of medical help. Watching from afar one person noted something wasn't quite right – plants kept appearing/peeping out of the back of the ambulance and by the doors. Searching for the bed and the patient in the ambulance was...

Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300…

Press Release Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million NCX 470 therapeutic profile positively received among U.S. eye care professionalsin a market survey conducted with a leading, independent research agencyPotential annual global net sales for NCX 470 estimated to reach at least $300 million within 8 years from the date of launches in U.S. and ChinaNicox currently seeking...

BioSenic provides further update on negotiations with its main creditors

INSIDE INFORMATION Agreement with the main creditors of BioSenic for a standstill running until October 2023 Mont-Saint-Guibert, Belgium, July 10 th, 2023, 7.00 am CEST – BIOSENIC(Euronext Brussels and Paris: BIOS), the innovative company addressing unmet medical needs in the areas of innate immunity, inflammation and organ/function repair, today announces a further update on its financial arrangements with its main historical creditors, Patronale, Monument and the European...

Sequana Medical announces first patient enrolled in MOJAVE, a US randomized…

PRESS RELEASE US study seeking to confirm strong efficacy data reportedin RED DESERT and SAHARAInitial data expected in Q4 2023 Ghent, Belgium – 10 July2023– Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that the first patient has been enrolled in its MOJAVE study.MOJAVE, a randomized controlled...

Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now…

Ad hoc announcement pursuant to Art. 53 LR The approximately 20 million US lives covered by CVS will now have easier and more affordable access to QUVIVIQAllschwil, Switzerland & Radnor , PA, United States – July 10, 2023Idorsia Ltd (SIX: IDIA) and Idorsia Pharmaceuticals US Inc. today announced that, effective immediately, CVS is covering QUVIVIQ ®(daridorexant) CIV on the Performance Drug List (PDL). Approximately 20 million people are enrolled in this CVS plan,...

SIAF: Disrupted epithelial barriers as a predictor of severe COVID-19…

Biomarkers of intact or defective epithelial barriers are associated with disease severity Biomarkers of intact or defective epithelial barriers are associated with disease severity The compromised epithelial barriers in the mucosas, particularly in gut mucosa facilitates the translocation of microbiota and their secreted metabolites, thus initiating or exacerbating inflammatory cascades in many inflammatory diseases. The research group of epithelial biology in the Swiss Institute of...

Two-vision debut for new CIIE friend

"MUJI wanted to deliver two visions at the event. First, to promote Chinese design to the world market; second, to demonstrate its determination to take root in China," said Shimizu Satoshi, chairman and managing director of MUJI (Shanghai) Company. "MUJI wanted to deliver two visions at the event. First, to promote Chinese design to the world market; second, to demonstrate its determination to take root inChina," saidShimizu Satoshi, chairman and managing director of MUJI (…

Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto®…

Ad hoc announcement pursuant to Art. 53 LR U.S. District Court for the District of Delaware ruled the Entresto (sacubitril / valsartan) 'combination patent' to be invalid Novartis will appeal to the U.S. Court of Appeals for the Federal Circuit to reverse the District Court's rulingNo generic Entresto product has received FDA approval as of todayPending a final appeal decision and other ongoing litigation involving multiple patents, any launch once generics receive FDA approval...

Groupe Casino: Extension of 3F Holding's offer

Extension of 3F Holding's offer Paris, 7 July 2023Casino announces that 3F Holding has extended the validity of its offer, filed on July 4 2023, to 10 July 2023. ***This press release was prepared solely for information purposes and should not be construed as a solicitation or an offer to buy or sell securities or related financial instruments. Likewise, it does not provide and should not be treated as providing investment advice. It has no connection with the specific...

Orion Corporation: Change in Orion Group Executive Management Board as of 30…

ORION CORPORATIONSTOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS 7 July 2023 at 14.30 EEST Orion Corporation: Change in Orion Group Executive Management Board as of 30 April 2024Jari Karlson, the Chief Financial Officer of the Orion Group and member of the Executive Management Board of the Orion Group has announced that he will step down from his position at Orion as of 30 April 2024 and that he will retire. He has worked in his current position since 2002...

Advanced FDA Cleared Magstim Horizon 3.0 Transcranial Magnetic Stimulation Now…

Approval by UKCA Empowers UK Physicians to Advance Care of Treatment Resistant Depression, Obsessive Compulsive Disorder, and Anxious Depression with Non-Invasive Brain Stimulation 1. The first company to manufacture and commercialize TMS as a treatment for brain disorders, Magstim technology has been cited in more than 16,000 published studies in the neuroscientific and clinical research.“Magstim was founded in Wales, where our TMS line is manufactured and continues to be advanced,”...

Microcatheters Market worth $1,142 million | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=184715728 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=184715728 Browse in-depth TOC on "Microcatheters Market" 120 - Tables 36 - Figures 180 - Pages Microcatheters Market Scope: Diagnostic Microcatheters segment to register significant growth rate over the forecast period of 2022-2028 Based on the product type, the...

Kexing Biopharm Makes it into China's Top 20 Biopharmaceutical Enterprises…

Kexing Biopharm has consistently prioritized and invested in scientific and technological advancements, which remain at the core of the company's mission and values. In 2022, Kexing Biopharm made significant strides in research and development, with a noteworthy investment of RMB 193 million, reflecting a remarkable growth of 57.21% compared to the corresponding period last year. Kexing Biopharmaceutical has witnessed the swift progress of several products, transitioning from development to…

Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes…

Married, three children, Maria Paola Chiesi joined the company in 1995. She gave an international dimension to marketing and charted the Group's strategic planning path. In 2015 she created and led the Shared Value & Sustainability department, which monitors and measures the company's impacts on the environment and society, implementing improvement plans. As a result of this work, Chiesi changed its bylaws becoming a Benefit Corporation and obtained the B Corp certification. Maria Paola is…

UZBEKISTAN CONFERENCE GUESTS TOUT EMERGING 'EURASIAN TIGER' ECONOMY

During a session on the topic of changing the country's image, a representative of the South Korean construction giant DL E&C Co., Ltd, said Uzbekistan will be the new 'Eurasian Tiger.' Responding to a suggestion that Uzbekistan was in some ways similar to South Korea 30 years ago — poised to become an Asian tiger,Minsu Jang, Civil Business Division Vice President of DL E&C, said, "I agree with you. I think the new big tiger is here. That's why we selected to participate in…

iWantGreatCare and Top Doctors merge to become the leading company for patient…

Alberto E. Porciani, CEO and Co-founder of Top Doctors, affirms the merger will bolster their technology offerings, delivering an inclusive service for medical professionals, centres, hospitals, and patients. IWGC's review system, he says, integrates seamlessly with PHIN (Private Healthcare Information Network) and the NHS (National Health Service). Alberto E. Porciani, CEO and Co-founder of Top Doctors, affirms the merger will bolster their technology offerings, delivering an inclusive…

Coloplast A/S - Announcement no. 03/2023 - Coloplast announces agreement to…

Coloplast has signed an agreement to acquire Kerecis, an innovative, fast-growing company in the biologics wound care segment, for up to USD 1.3 billion (around DKK 8.9 billion), of which USD 1.2 billion (around DKK 8.2 billion) is an upfront cash payment Kerecis represents an attractive opportunity to strategically strengthen Coloplast's presence in the advanced wound care market by entering the high-growth, US-centric biologics segmentWith a mission to improve wound care treatment,...

FDA grants traditional approval for LEQEMBI® (lecanemab-irmb) for the treatment…

"The full, traditional approval of LEQEMBI in the US, combined with the broad Medicare reimbursement, is a paradigm-shifting step in the fight against Alzheimer's disease," said Gunilla Osswald, CEO of BioArctic. "Doctors in the US will now have a tool to combat this terrible chronic disease already at an early stage, with the potential to provide clinically meaningful benefit for patients and their families. More than two decades of research and development has led up to this…

Altri Comunicati